204
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Ripasudil Eyedrops Ameliorated Bullous Keratopathy Complicated with Cytomegalovirus Corneal Endotheliitis: A Case Report

, MD, , MD, PhD, , MD, PhD, , MD, PhD, , MD & , MD, PhD
Pages 207-210 | Received 02 Jun 2021, Accepted 28 Sep 2021, Published online: 02 Nov 2021
 

ABSTRACT

Purpose

We describe a case of bullous keratopathy complicated with cytomegalovirus (CMV) corneal endotheliitis that was successfully treated with ripasudil eye drops.

Methods

A retrospective case report.

Results

A 65-year-old female patient diagnosed with CMV-associated anterior uveitis in the right eye was referred to us when anterior uveitis recurred with bullous keratopathy. Initial best-corrected visual acuity (BCVA) was 0.4 (decimal visual acuity). Her condition did not improve with anti-CMV treatment, and BCVA decreased to 0.07. At this point, intraocular pressure (IOP) was 20 mmHg, and ripasudil eye drops were started for IOP control. After 1 month, not only had IOP decreased to 14 mm Hg but the condition of the corneal edema had also improved. The central corneal thickness decreased to a normal level, and the BCVA recovered to 0.8.

Conclusion

Ripasudil eye drops not only lower IOP in patients with CMV corneal endotheliitis but may also have the potential to treat bullous keratopathy.

Acknowledgments

The authors thank Mr. Tim Hilts for reviewing this manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Ethical approval

This study was approved by the Institutional Review Board of Tohoku University Hospital (No. 22440) and was conducted in accordance with the tenets of the Declaration of Helsinki. Written informed consent was obtained for publication by the patient.

Additional information

Funding

The author(s) reported that there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.